1. Scrip
  2. >>Advanced Therapies
  3. >>Gene Therapies

Don’t Count Pfizer Out In DMD

 
• By Jessica Merrill

Pfizer reminded investors it still has a gene therapy in Phase III development for Duchenne muscular dystrophy after Sarepta’s disappointing Phase III readout.

boxing ring
Pfizer is still in the fight against DMD • Source: Shutterstock

Sarepta Therapeutics, Inc.’s gene therapy setback in Duchenne muscular dystrophy (DMD) could be Pfizer Inc.s gain. One day after Sarepta announced that the Phase III confirmatory trial testing Elevidys (delandistrogene moxeparvovec-rokl) in DMD failed to meet the primary endpoint, Pfizer said it remains hopeful that its DMD gene therapy, fordadistrogene movaparvovec, could yield stronger Phase III data.

Key Takeaways
  • Pfizer's DMD gene therapy is in Phase III with interim data expected by the end of the year.
  • Pfizer has deprioritized gene therapy more generally but...

“This makes our gene therapy, in a way, the main game,” worldwide president R&D Mikael Dolsten said during the company’s third quarter sales and earnings call on 31 October.

More from Gene Therapies

More from Advanced Therapies

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Gilead Pipeline Progress Offsets Oncology Sales Slowdown

 
• By Alaric DeArment

Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.